These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37414008)

  • 1. Adjuvant immune checkpoint blockade revisited.
    van Waalwijk van Doorn-Khosrovani SB; Huisman A; Roy AP; Koole S; Timmers L; Blank C; Gelderblom H
    Lancet Oncol; 2023 Jul; 24(7):717-719. PubMed ID: 37414008
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockade.
    Asdourian MS; Shah N; Jacoby TV; Semenov YR; Otto T; Thompson LL; Dee EC; Reynolds KL; Chen ST
    J Am Acad Dermatol; 2023 Feb; 88(2):485-487. PubMed ID: 35738514
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy.
    Zhou N; Velez MA; Owen D; Lisberg AE
    J Natl Compr Canc Netw; 2020 Sep; 18(9):1287-1290. PubMed ID: 32886906
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Germline Variants Associated with Toxicity to Immune Checkpoint Blockade.
    Jones JO; Mitchell TJ; Stewart GD
    Eur Urol; 2023 Dec; 84(6):597. PubMed ID: 36964039
    [No Abstract]   [Full Text] [Related]  

  • 5. [A decade of checkpoint inhibitors: current standard of care and future trends].
    Reischer A; Kruger S; von Bergwelt-Baildon M
    Dtsch Med Wochenschr; 2021 Sep; 146(17):1108-1118. PubMed ID: 34448187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of pre-existing drug allergies with cutaneous immune-related adverse events among patients on immune checkpoint inhibitor therapy.
    Jacoby TV; Otto TS; Asdourian MS; Shah N; Farcasanu M; Chang MS; Thompson LL; Reynolds KL; Chen ST
    Br J Dermatol; 2022 Sep; 187(3):424-426. PubMed ID: 35290662
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune-Checkpoint Blockade Therapy in Lymphoma.
    Kuzume A; Chi S; Yamauchi N; Minami Y
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models.
    Park BC; Stone CA; Dewan AK; Johnson DB
    Immunol Allergy Clin North Am; 2022 May; 42(2):285-305. PubMed ID: 35469619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma.
    Isazadeh A; Hajazimian S; Garshasbi H; Shadman B; Baghbanzadeh A; Chavoshi R; Taefehshokr S; Farhoudi Sefidan Jadid M; Hajiasgharzadeh K; Baradaran B
    J Cell Physiol; 2021 Feb; 236(2):791-805. PubMed ID: 32592235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report.
    Shantzer LB; Dougherty SC; Bolte F; Melson JW; Reed DR; Lynch AC; Gentzler RD; Novicoff W; Hall RD
    Clin Lung Cancer; 2023 Mar; 24(2):e60-e64. PubMed ID: 36526550
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issues.
    Ferranti M; Cicogna GT; Messina F; Alaibac M
    Immunotherapy; 2021 Jul; 13(10):795-798. PubMed ID: 33955235
    [No Abstract]   [Full Text] [Related]  

  • 12. Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.
    Chuang YC; Tseng JC; Huang LR; Huang CM; Huang CF; Chuang TH
    Front Immunol; 2020; 11():1075. PubMed ID: 32547560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ["Immune checkpoint inhibitors in oncology"].
    Daëron M; Vivier É
    Rev Prat; 2021 Apr; 71(4):374-379. PubMed ID: 34161001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.
    Li N; Wang G; Hou X; Tai R; Huang S; He Z; Lei L; Xu S; Yang S
    Int Immunopharmacol; 2022 Jul; 108():108803. PubMed ID: 35569432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Blockade and Targeted Therapies in Esophageal Cancer.
    Yang J; Janjigian YY
    Thorac Surg Clin; 2022 Nov; 32(4):467-478. PubMed ID: 36266034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review).
    Yu S; Xiong G; Zhao S; Tang Y; Tang H; Wang K; Liu H; Lan K; Bi X; Duan S
    Int J Mol Med; 2021 Feb; 47(2):444-454. PubMed ID: 33416134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
    Willsmore ZN; Coumbe BGT; Crescioli S; Reci S; Gupta A; Harris RJ; Chenoweth A; Chauhan J; Bax HJ; McCraw A; Cheung A; Osborn G; Hoffmann RM; Nakamura M; Laddach R; Geh JLC; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Josephs DH; Papa S; Lacy KE; Karagiannis SN
    Eur J Immunol; 2021 Mar; 51(3):544-556. PubMed ID: 33450785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of immune checkpoint inhibitors in immuno-oncology.
    Jacob JB; Jacob MK; Parajuli P
    Adv Pharmacol; 2021; 91():111-139. PubMed ID: 34099106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.
    Hosseinzadeh R; Feizisani F; Shomali N; Abdelbasset WK; Hemmatzadeh M; Gholizadeh Navashenaq J; Jadidi-Niaragh F; Bokov DO; Janebifam M; Mohammadi H
    IUBMB Life; 2021 Nov; 73(11):1293-1306. PubMed ID: 34538007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.